8-K: CG Oncology Reports Strong Q2, Clinical Wins

CG Oncology announced its second quarter 2025 financial results, highlighted by positive clinical trial data for cretostimogene and a favorable outcome in the ANI Pharmaceuticals litigation.

Summary

• CG Oncology reported a net loss of $41.4 million, or ($0.54) per share, for the second quarter ended June 30, 2025, compared to a net loss of $18.9 million, or ($0.28) per share, for the same period in 2024.
• Research and Development (R&D) expenses increased to $31.3 million for Q2 2025 from $18.5 million for Q2 2024, primarily due to increased clinical trial expenses and compensation costs.
• General and Administrative (G&A) expenses rose to $17.4 million for Q2 2025 from $7.5 million for Q2 2024, driven by personnel-related expenses and legal costs.
• Cash, cash equivalents, and marketable securities stood at $661.1 million as of June 30, 2025, down from $688.4 million as of March 31, 2025, but are expected to fund operations into the first half of 2028.
• The company presented 'best-in-disease' durability and tolerability data from the Phase 3 BOND-003 Cohort C trial for cretostimogene, showing a 75.5% complete response (CR) at any time, with 50.7% CR at 12 months and 42.3% CR at 24 months by K-M estimation.
• Median duration of response in BOND-003 Cohort C is 28 months and is ongoing, with 97.3% of patients free from progression to muscle invasive disease at 24 months.
• BOND-003 Cohort P showed an estimated 90.5% high-grade recurrence-free survival at 3 and 9 months in 24 treated patients.
• CG Oncology initiated the CORE-008 Cohort CX clinical trial evaluating cretostimogene in combination with gemcitabine for high-risk (HR) BCG-exposed NMIBC.
• A jury in the Superior Court of the State of Delaware unanimously found in favor of CG Oncology against ANI Pharmaceuticals, ruling that CG Oncology owes no future royalties (5% on commercial sales) or other payments under the 2010 agreement.

Sentiment

Score: 8

Explanation: The filing presents overwhelmingly positive clinical and legal developments that significantly de-risk the company's lead asset and accelerate its path to market. While financial losses increased, this is typical for a late-stage biotech, and the strong cash runway provides stability. The 'best-in-disease' data and elimination of future royalties are major catalysts.

Positives

• Presented 'best-in-disease' durability and tolerability data for cretostimogene in BOND-003 Cohort C, demonstrating a 75.5% complete response at any time and 42.3% at 24 months, with 97.3% of patients free from progression to muscle invasive disease at 24 months.
• Reported promising early signal in BOND-003 Cohort P with an estimated 90.5% high-grade recurrence-free survival at 3 and 9 months.
• Achieved a unanimous jury verdict in favor of CG Oncology against ANI Pharmaceuticals, eliminating a 5% future royalty on commercial sales of cretostimogene and any other payments.
• Anticipates initiating the Biologics License Application (BLA) submission for cretostimogene monotherapy in high-risk BCG-unresponsive NMIBC in the fourth quarter of 2025.
• Maintains a strong cash position of $661.1 million as of June 30, 2025, projected to fund operations into the first half of 2028.

Negatives

• Net loss increased to $41.4 million for Q2 2025 from $18.9 million for Q2 2024.
• Research and Development (R&D) expenses increased by 69.2% to $31.3 million for Q2 2025 from $18.5 million for Q2 2024.
• General and Administrative (G&A) expenses increased by 132.2% to $17.4 million for Q2 2025 from $7.5 million for Q2 2024.
• Cash, cash equivalents, and marketable securities decreased from $688.4 million as of March 31, 2025, to $661.1 million as of June 30, 2025.

Risks

• Interim results of a clinical trial are not necessarily indicative of final results and may materially change as patient enrollment continues or more data becomes available.
• Potential for delays in the commencement, enrollment, and completion of clinical trials, including the BOND-003 and PIVOT-006 trials.
• Capital resources may be used sooner than expected and may be insufficient to achieve anticipated milestones.
• Dependence on third parties in connection with manufacturing, shipping, and clinical and preclinical testing.
• Results from earlier clinical trials and preclinical studies may not be predictive of future results.
• Unexpected adverse side effects or inadequate efficacy of cretostimogene could limit its development, regulatory approval, and/or commercialization.

Future Outlook

CG Oncology is poised to initiate its Biologics License Application (BLA) submission for cretostimogene in the fourth quarter of 2025 for the treatment of patients with high-risk NMIBC unresponsive to BCG. The company also anticipates completing Phase 3 enrollment for PIVOT-006 in Q3 2025 and expects topline data from BOND-003 Cohort P and CORE-008 Cohort A in Q4 2025, with CORE-008 Cohort CX data expected in 1H 2026. Existing cash and marketable securities are projected to fund operations into the first half of 2028.

Management Comments

• "In the second quarter, we announced best-in-disease durability and tolerability from the Phase 3 BOND-003 Cohort C registrational trial, building upon the body of evidence demonstrating the power of cretostimogene’s unique dual mechanism of action, and its potential to treat intermediate-risk and high-risk NMIBC."
• "We remain laser focused on bringing forward cretostimogene, our potentially breakthrough backbone treatment to patients."
• "The recent positive outcome of the ANI litigation allows us to continue to focus our resources and energy on delivering this innovative therapy."
• "We are poised to initiate our BLA submission for cretostimogene in the fourth quarter of the year for the treatment of patients with HR NMIBC unresponsive to BCG."

Industry Context

This announcement positions CG Oncology as a significant player in the bladder cancer treatment landscape, particularly for Non-Muscle Invasive Bladder Cancer (NMIBC). The development of cretostimogene, an oncolytic immunotherapy, aligns with the broader industry trend towards innovative, targeted therapies and immunotherapies for cancer. The focus on a 'bladder-sparing therapeutic' addresses a critical unmet need for patients seeking alternatives to radical cystectomy, potentially establishing cretostimogene as a backbone treatment in this disease area.

Comparison to Industry Standards

• Cretostimogene's BOND-003 Cohort C data demonstrated 'best-in-disease durability and tolerability,' suggesting superior or highly competitive efficacy and safety profiles compared to existing or developing treatments for high-risk BCG-unresponsive NMIBC.
• The 75.5% complete response rate at any time and 42.3% at 24 months, coupled with 97.3% freedom from progression to muscle invasive disease at 24 months, sets a high benchmark for bladder-sparing therapies in this challenging patient population.
• The favorable outcome of the ANI Pharmaceuticals litigation, eliminating a 5% future royalty, significantly improves the commercial viability and profitability outlook for cretostimogene compared to similar drug development programs that may carry substantial royalty burdens.

Legal Proceedings

• A jury in the Superior Court of the State of Delaware unanimously found in favor of CG Oncology on all claims in a March 2024 lawsuit brought by ANI Pharmaceuticals, Inc. (ANI).
• The jury unanimously rejected all of ANI's claims for unjust enrichment damages.
• Judge Sheldon K. Rennie ruled on July 16, 2025, that ANI was not entitled to any royalties on future sales of cretostimogene grenadenorepvec.
• As a result, CG Oncology will not owe ANI a future royalty of 5% on commercial sales of cretostimogene, no damages have been awarded to ANI, and there are no further payments due to ANI under the 2010 agreement.
• The company will continue to vigorously defend any post-trial motions and appeals brought by ANI.

Stakeholder Impact

• Shareholders: Highly positive impact due to strong clinical data, elimination of a significant future royalty obligation, and clear regulatory path, which could lead to increased share price and long-term value.
• Patients: Significant positive impact as cretostimogene shows potential as a 'best-in-disease' bladder-sparing therapeutic for NMIBC, offering a new treatment option.
• Employees: Positive impact due to the company's strong progress, clear strategic direction, and continued focus on delivering innovative therapies, potentially ensuring job stability and growth opportunities.
• Creditors/Suppliers: Stable financial position with sufficient cash runway into 2028, indicating continued ability to meet financial obligations.

Next Steps

• Complete Phase 3 enrollment for PIVOT-006 (intermediate-risk NMIBC) in 3Q'25.
• Initiate Biologics License Application (BLA) submission for cretostimogene monotherapy in HR BCG-unresponsive NMIBC with CIS with or without Ta/T1 disease in 4Q'25.
• Release topline data from the Phase 3 clinical trial of cretostimogene monotherapy in BOND-003 Cohort P (HR BCG-unresponsive NMIBC in Ta/T1 disease without CIS) in 4Q'25.
• Release topline data from the Phase 2 clinical trial of cretostimogene monotherapy in CORE-008 Cohort A (HR BCG-naive NMIBC with CIS +/Ta/T1) in 4Q'25.
• Release topline data from the Phase 2 clinical trial of the combination of cretostimogene with gemcitabine in CORE-008 Cohort CX (HR BCG-exposed NMIBC) in 1H26.
• Vigorously defend any post-trial motions and appeals brought by ANI Pharmaceuticals.

Key Dates

Recommendation

The company reported 'best-in-disease' durability data for its lead candidate, cretostimogene, in a Phase 3 trial, with a clear plan for BLA submission in Q4 2025. This, coupled with a decisive legal victory eliminating a significant future royalty obligation, de-risks the asset considerably and positions the company for potential market entry. While operating expenses and net loss increased, this is expected for a late-stage biopharmaceutical company advancing its pipeline, and the strong cash position into 2028 provides ample runway. The clinical and regulatory progress are paramount for a biotech and are overwhelmingly positive.

Keywords

Oncology, Bladder Cancer, NMIBC, Cretostimogene, Biopharmaceutical, Clinical Trials, Immunotherapy, CGON, Urologic Cancer, SEC Filing